ANALYSIS OF THE NEUROLOGICAL MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS WITH CLINICAL PARAMETERS OF THE DISEASE

Abstract

Objective: To analyze the presence of neurological manifestations in Systemic Lupus Erythematosus (SLE) patients and associate the disease’s diverse autoantibodies and other clinical manifestations. Method: A retrospective cross - sectional observational study was carried with data collected at the Municipal Polyclinic of Palhoça Unisul - AME - and at Clínica Movimento between September and November 2018. Neurological manifestations were the clinical and laboratory variables considered. Results: 110 individuals were analyzed, in whom neurological manifestations was found in 28.2% of them. Psychiatric disorder was the most prevalent manifestation (21.8%), followed by cerebrovascular disease (11.8%), movement disorder (5.5%), convulsive disorder (2.7%), polyneuropathy (10.9%), autonomic alteration (5,5%) and cranial neuropathy (9.1%). The manifestation of seizures was associated with cutaneous lesions (4.1%, p = 0.001) and thrombocytopenia (23.1%, p = 0.021). Patients with cerebrovascular disease presented hemolytic anemia (50.0%, p = 0.042) and positive tests for anti-B2GP1-IgG and anti-B2GP1-IgM (23.8%, p = 0.017, p = 0.013). Movement disorder was associated with hemolytic anemia (50.0%, p = 0.012). An association between Raynaud's phenomenon (14.3%, p = 0.036), anti-SSB/La positivity (20.0%, p = 0.035), lupus anticoagulant (16.7%, p = 0.004) and anti-B2GP1-IgG and anti-B2GP1-IgM (23.8%, p = 0.017, p = 0.013) was also observed in cases of autonomic alterations. Polyneuropathy was associated with cutaneous SLE (13.3%, p = 0.038), lupus anticoagulant positivity (23.3%, p = 0.019) and anti-B2GP1-IgM (23.8%, p = 0.013). Conclusion: Neurological manifestations in patients with SLE are frequent. Its presence is associated with cutaneous lesions, anti-B2GP1-IgG e anti-B2GP1-IgM.